789-P: Discovery of a Novel, Long-Acting Amylin Receptor Agonist for Body Weight Control

Introduction CTR: 0.41 nM vs 0.45 nM). In SD rats, Cmpd C decreased body weight by 7.36% compared to 6.28% for cagrilintide over 48 hours. In DIO rats, body weight loss after end of dosing (Day 11) was 8.19% for Cmpd C and 7.55% for cagrilintide. In cynomolgus monkeys, Cmpd C showed comparable PK to cagrilintide. Importantly, Cmpd C showed superior thermal stability to cagrilintide at pH 7.4. While 44.83% of cagrilintide was degraded after 10 days, Cmpd C was reduced by 4.26% after 20 day incubation. Conclusion: Overall, Cmpd C demonstrated potency and PK comparable to cagrilintide. Moreover, Cmpd C exhibited greater stability at pH 7.4 than cagrilintide, providing the opportunity to co-formulate with GLP-1 analogs. Formulation of GLP-1 and amylin in a single vial will improve ease of use and reduce cost. Disclosure Y. Li: Employee; Sciwind Biosciences. H. Zou: Employee; Sciwind Biosciences. X. Wu: Employee; Sciwind Biosciences. R. Zhu: Employee; Sciwind Biosciences. R. Wang: Employee; Sciwind Biosciences. S. Hao: Employee; Sciwind Biosciences. Z. Li: Employee; Sciwind Biosciences. Y. Wang: Employee; Sciwind Biosciences. J. Deng: Employee; Sciwind Biosciences. H. Wang: Employee; Sciwind Biosciences. F. Peng: Employee; Sciwind Biosciences. C.L. Jones: Employee; Sciwind Biosciences. M. Fenaux: None. Funding Sciwind Biosciences